A newly engineered brain-delivered antibody targeting alpha-synuclein aggregates, implicated in synucleinopathies like Parkinson’s disease, demonstrates potential for mitigating neurodegeneration. This monoclonal antibody, developed by An, McInnis, Kim, and colleagues, offers a promising therapeutic strategy aimed at the pathological hallmark of Parkinson's, potentially altering disease progression and improving patient outcomes.